JSK Therapeutics is a privately held, late preclinical-stage biotechnology company focused on creating novel first-in-class Nitric Oxide donor molecules with potent and selective activity against Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), and Ewing's sarcoma. JSK's lead drug candidate JS-K has been scaled to GMP Level and the stability studies are ongoing. Non-GLP safety studies in rats and dogs have raised no safety concerns at dose levels deemed to be highly efficacious. The company plans to enter clinical trials in Q1, 2017.Type your paragraph here.
View Top Employees from JSK Therapeutics| Website | http://www.jskthera.com |
| Revenue | $6 million |
| Employees | View employees |
| Founded | 2008 |
| Address | 9758 Cervantes Cir, Sandy City, Utah 84092, US |
| Phone | (610) 772-3551 |
| Industry | Business Services General, Pharmaceutical, Drug Discovery, Business Services, Health Care, Biotechnology, Therapeutics |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies |
Looking for a particular JSK Therapeutics employee's phone or email?
JSK Therapeutics Questions
The JSK Therapeutics annual revenue was $6 million in 2024.
JSK Therapeutics is based in Sandy City, Utah.
The NAICS codes for JSK Therapeutics are [541714, 541, 54, 54171, 5417].
The SIC codes for JSK Therapeutics are [873, 87].
